Glycostem’s oNKord Cell-based Therapy Granted FDA Orphan Drug Designation
The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to oNKord, Glycostem Therapeutics‘ cell-based therapy for the…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Cytovia, Inserm Partnering on NK-based Immunotherapies for Myeloma
A recent collaboration between Cytovia Therapeutics and Inserm, the French National Institute of Health and Medical Research, aims to advance new immunotherapies against…
NCI Awards $1.7M for Bone Therapy Research to Prevent or Delay Cancer Relapse
The National Cancer Institute (NCI) has awarded $1.7 million to support the work of a University of Arkansas for Medical…
Stand Up to Cancer Awards $100K for Research About Precursor Multiple Myeloma
Stand Up To Cancer (SU2C) has awarded the 2020 SU2C Sharp Tank Award to Catherine Marinac, PhD, to support her research examining how…
Melflufen Open to Select Adults With Advanced Multiple Myeloma in US
Oncopeptides has formally opened sEAPort, its open-label expanded access program allowing adults with…
Planned Study Aims for Way to Personalize Multiple Myeloma Treatment
A nonprofit–industry partnership, led by RCSI University of Medicine and Health Sciences of Dublin and SkylineDx, aims to advance genetic testing to better guide doctors…
